Why is DRRX a gainer in the penny stock market?

The stock price of DRRX has experienced a significant increase from July 22 to July 29. The substantial rise in Durect's (DRRX) stock price can be attributed to **Acquisition Agreement with Bausch Health**. On July 28, 2025, DURECT Corporation entered into a merger agreement with Bausch Health Americas, Inc., where Bausch will acquire DURECT for $1.75 per share in cash, with potential additional milestone payments. This acquisition is expected to close in the third quarter of 2025. |code|Ticker|Name|Date|Percentage Change|market_code| |---|---|---|---|---|---| |DRRX|DRRX.O|Durect|20250725|-3.4377|186| |DRRX|DRRX.O|Durect|20250728|-2.5908|186| The acquisition agreement with Bausch Health has led to a significant premium on DURECT's shares, with the acquisition price representing a 217% premium over the prior closing price. This premium reflects the potential value that Bausch Health sees in DURECT's lead asset, larsucosterol, which has shown promising results in Phase 2 trials for treating alcoholic hepatitis. The transaction is expected to close in the third quarter of 2025, subject to customary closing conditions including the tender of a majority of DURECT’s outstanding shares. The potential for this acquisition to bolster Bausch Health’s commitment to hepatology and liver disease treatments, particularly with the promising development of larsucosterol for alcoholic hepatitis, has contributed to the positive sentiment surrounding DURECT's stock. In conclusion, DRRX's gain in the penny stock market is primarily driven by the acquisition agreement with Bausch Health, which has led to a significant premium on DURECT's shares and a positive outlook for its lead asset, larsucosterol.